These ASX 200 blue chip shares could rise 25% to 40%

Analysts are bullish on these big names. Let's see what they are recommending.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Cochlear, a leader in hearing devices, is recommended by UBS due to its dominant market share and growth potential, with a projected 30% upside as it continues to innovate and expand product offerings.
  • CSL, despite recent pressures from its Seqirus spin-off and regulatory concerns, remains a strong investment due to its robust demand and strategic investments in plasma collection and therapy development, with Morgans forecasting a nearly 40% rise.
  • REA Group, dominating Australia's online property advertising, is expanding into financial services and data products, with Bell Potter suggesting a 25% upside, benefiting from potential interest rate cuts and its strategic market positioning.

Blue chip shares are often the cornerstone of long-term portfolios. They offer stability, strong market positions, and the ability to grow earnings through multiple economic cycles.

And with recent volatility pulling several high-quality names down meaningfully, analysts see buying opportunities emerging across the ASX 200.

For example, here are three ASX 200 blue chip shares that brokers have flagged as top buys right now. They are as follows:

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company

Image source: Getty Images

Cochlear Ltd (ASX: COH)

Cochlear could be an ASX 200 blue chip share to buy. It is a leader in implantable hearing devices globally. Demand for its products continues to rise as ageing populations grow and access to hearing treatments expands worldwide.

The company's ongoing investment in research and new product development has helped it maintain its dominant market share and support steady revenue growth. And with a strong balance sheet, rising volumes, and a history of delivering consistent earnings and dividends, Cochlear continues to stand out as a reliable long-term compounder.

UBS is a fan of the company and has a buy rating and a $350.00 price target on the stock. This implies around 30% upside from current levels.

CSL Ltd (ASX: CSL)

Global biotech heavyweight CSL has come under pressure in recent months, with investor sentiment dampened by the planned Seqirus spin-off, regulatory uncertainty, and a slower-than-hoped recovery in plasma margins. But despite recent share price weakness, CSL's long-term fundamentals remain strong.

CSL continues to invest in expanding its plasma collection network, developing new therapies, and strengthening its manufacturing footprint in the United States. Demand for its core plasma-derived products remains robust, and analysts expect earnings momentum to rebuild as temporary headwinds ease.

So, with its shares trading close to a 52-week low, CSL's valuation looks significantly more appealing than it has in years.

Morgans sees meaningful upside from current levels. It has a buy rating and a $249.51 price target on its shares, which suggests that they could rise almost 40%.

REA Group Ltd (ASX: REA)

Finally, REA Group could be an ASX 200 blue chip share to buy now. It dominates Australia's online property advertising market, supported by powerful pricing power, strong customer relationships, and significant digital scale.

It has also expanded beyond listings into financial services, data products, and international investments, broadening its growth runway. With more interest rate cuts potentially coming in 2026, the company's premium positioning and deep integration into the property ecosystem give it substantial leverage to any improvement in listing volumes.

Bell Potter remains bullish. It has a buy rating and $244.00 price target on its shares, implying nearly 25% upside from current levels.

Motley Fool contributor James Mickleboro has positions in CSL, Cochlear, and REA Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ASX Share Market News

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Broker says this ASX 200 stock could rocket 50%+ in 12 months

Bell Potter has good things to say about this stock.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news.
52-Week Lows

2 ASX shares near 52-week lows I'd buy today

Amid share price pain, I think these businesses are great buys!

Read more »

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
ASX Share Market News

5 things to watch on the ASX 200 on Thursday

Will the Australian share market end its winning streak today?

Read more »

Broker Notes

2 ASX 200 stocks drawing fresh buy ratings this week 

These shares have solid upside.

Read more »

An old-fashioned panel of judges each holding a card with the number 10
Share Gainers

Here are the top 10 ASX 200 shares today

It was one for the record books this Wednesday.

Read more »

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Magellan and Ramsay Health Care shares

A leading expert forecasts growing headwinds for Magellan and Ramsay Health Care shares. But why?

Read more »

A beautiful ocean vista is shown with a woman whose back is to the camera holding her arms up in triumph as she stands at the top of a rock feeling thrilled that ASX 200 shares are reaching multi-year high prices today
ASX Share Market News

Record breaker! The ASX 200 just hit a fresh all-time high

Investors just sent the ASX 200 into uncharted territory.

Read more »

Pilot on the phone looking distraught.
Broker Notes

Sell alert! Why this expert is ditching Qantas shares for this ASX 200 defence stock

A leading expert is selling Qantas shares and buying this surging ASX 200 defence stock instead. But why?

Read more »